相关实验视频

Updated: Jun 25, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

在患有抗凝失败患者的患者中,左心室尾封闭:抗凝失败与抗凝的禁忌

Errol W Aarnink¹, Moniek Maarse¹, Nicolai Fierro²

¹Department of Cardiology, Sint Antonius Ziekenhuis, Nieuwegein, the Netherlands; Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands.

JACC. Cardiovascular interventions

|May 25, 2024

概括

左心房尾阻塞 (LAAO) 有效地保护心房患者免受中风,即使那些经历事件尽管口服抗凝治疗. 这种程序显示了与OAT禁忌患者相比较的中风率.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
医疗器械医疗器械

背景情况:

左心房尾阻塞 (LAAO) 为心房动 (AF) 患者提供心血管保护,无法使用口服抗凝疗 (OAT).
在OAT治疗期间经历血栓事件的患者具有高复发风险,并且可能从LAAO中受益.

研究的目的:

评估LAAO在AF患者的疗效,这些患者在OAT上发生了血栓事件.
为了比较这个群体中的LAAO结果与OAT禁忌患者中的LAAO,以及历史数据.

主要方法:

在STR-OAC LAAO合作中,包括接受LAAO的OAT血栓事件患者.
倾向性得分匹配用于将这一队列与EWOLUTION注册表 (OAT禁忌患者) 进行比较.
主要结局是缺血性中风,与没有OAT的历史数据进行比较.

主要成果:

在STR-OAC LAAO和EWOLUTION队列之间,缺血性中风发生率没有显著差异 (2.5%对1.9%).
与EWOLUTION相比,STR-OAC LAAO患者的血栓栓塞风险较高,但出血风险较低.
与没有OAT的历史数据相比,缺血性中风的相对风险降低显著 (STR-OAC LAAO的70%;EWOLUTION的78%).

结论:

在OAT发生血栓事件的患者中,LAAO显示的中风率与OAT禁忌的人群相比较.
风险概况不同,在STR-OAC LAAO组中,血栓栓塞的风险更高,出血的风险更低.
尽管OAT,但LAAO对于经历缺血事件的患者是一个潜在的考虑因素,等待随机试验数据.

关键词:

抗凝失败是因为抗凝失败.心房动是心房动的一种.缺血性中风中风左心房附属体封闭闭塞的情况

更多相关视频

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...